Baxter International Raises Full-Year Guidance Amid Operational Turnaround and Debt Reduction
Baxter International (BAX) reported strong third-quarter 2026 results, characterized by a 5% organic increase in global sales to $3 billion. The company raised its full-year guidance for both organic sales growth and adjusted earnings, signaling an effective operational turnaround following previous manufacturing challenges. Management is prioritizing balance sheet strength, aiming to reach a net leverage target of approximately three times earnings by year-end after retiring $864 million in debt through a cash tender offer. Additionally, the company is simplifying its manufacturing footprint by discontinuing cephalosporin production at its Round Lake facility to resolve FDA regulatory concerns and streamline operations. Long-term efficiency is being driven by 'Baxter GPS,' an internal operating system that has completed over 700 process initiatives this year. These improvements have already yielded tangible results, such as a 10% reduction in manufacturing cycle times for blood pressure cuffs without additional capital expenditure.

Tickers: $BAX
Topics: debt reduction earnings report guidance raise manufacturing operations product discontinuation